- Trials with a EudraCT protocol (168)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
168 result(s) found for: Cardiac Pet.
Displaying page 1 of 9.
EudraCT Number: 2022-000686-40 | Sponsor Protocol Number: pulsar | Start Date*: 2023-05-04 | |||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||
Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis | |||||||||||||
Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005384-16 | Sponsor Protocol Number: FLORAMICAR | Start Date*: 2016-04-26 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl... | ||||||||||||||||||
Medical condition: Patients with high clinical suspicion of cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002160-14 | Sponsor Protocol Number: 20160516 | Start Date*: 2016-11-22 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: 68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. | ||
Medical condition: Sarcoidosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001660-38 | Sponsor Protocol Number: FLORAMICAR2 | Start Date*: 2018-01-18 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective triple-arm, monocentric, phase-II explorative study on evaluation of diagnostic efficacy of the PET tracer (18F)-florbetaben (Neuraceq®) in patients with cardiac amyloidosis - FLORAMI... | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003911-23 | Sponsor Protocol Number: 1319902 | Start Date*: 2016-10-14 |
Sponsor Name:CHU Toulouse | ||
Full Title: Evaluation of cardiac uptake during a PET examination 18F Flutematamol (Vizamyl®) in cardiac damage amyloid. | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004627-16 | Sponsor Protocol Number: 70233 | Start Date*: 2020-11-25 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Clinical Validation of Quantitative Flutemetamol PET/CT in Cardiac Amyloidosis | |||||||||||||
Medical condition: Cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002483-31 | Sponsor Protocol Number: UZBRU_VHH2_2 | Start Date*: 2020-11-30 |
Sponsor Name:UZ Brussel | ||
Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ... | ||
Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004392-23 | Sponsor Protocol Number: T189/2016 | Start Date*: 2018-02-08 |
Sponsor Name:Turku University Hospital | ||
Full Title: 68Ga-NODAGA-RGD cardiac PET in patients with acute myocardial infarction or chronic total coronary occlusion | ||
Medical condition: Acute or chronic coronary artery occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002557-29 | Sponsor Protocol Number: SK_DMDPA-03 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Synektik Spółka Akcyjna | |||||||||||||
Full Title: A Phase III Study of [11C]-DMDPA Tracer for Positron Emission Tomography PET-CT Myocardial Perfusion Imaging (MPI). | |||||||||||||
Medical condition: Known or suspected acute coronary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024044-15 | Sponsor Protocol Number: BMS747158-301 | Start Date*: 2011-06-08 | |||||||||||
Sponsor Name:Lantheus Medical Imaging, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know... | |||||||||||||
Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001254-17 | Sponsor Protocol Number: CLCZ696B2320 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved e... | |||||||||||||
Medical condition: Heart Failure with preserved ejection fraction (HF-pEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) DE (Completed) ES (Completed) BG (Completed) NL (Completed) PL (Completed) BE (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003806-18 | Sponsor Protocol Number: IC2014-16 | Start Date*: 2016-03-24 |
Sponsor Name:INSTITUT CURIE | ||
Full Title: IMPROVEMENT OF LOCAL CONTROL IN SKULL BASE AND SPINE CHORDOMAS TREATED BY SURGERY AND PROTONTHERAPY TARGETING HYPOXIC CELLS REVEALED BY POSITRON EMISSION TOMOGRAPHY NITROIMIDAZOLE ([18F]FAZA) PET/C... | ||
Medical condition: Chordomas of the skull base, spine and sacrum | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002678-29 | Sponsor Protocol Number: BMS747158-302 | Start Date*: 2013-02-21 | |||||||||||
Sponsor Name:Lantheus Medical Imaging, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know... | |||||||||||||
Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002670-40 | Sponsor Protocol Number: NL44913.029.13 | Start Date*: 2015-09-09 | |||||||||||
Sponsor Name:VU University Medical Center (VUmc) | |||||||||||||
Full Title: Noninvasive Imaging of Vulnerable Inflammatory Coronary Plaque using Cardiac PET/CT in Humans: a feasibility study | |||||||||||||
Medical condition: The IMP (PET-tracer) will be investigated in patients 24-72 hours after an acute coronary syndrome without excessive enzyme release (CK < 180 U/L) during PET scanning protocol. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000029-29 | Sponsor Protocol Number: 95105003 | Start Date*: 2018-12-11 |
Sponsor Name:VU University Medical Center | ||
Full Title: Extra energy for hearts with a genetic defect: ENERGY trial | ||
Medical condition: Hypertrophic cardiomyopathy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005011-14 | Sponsor Protocol Number: GE-265-303 | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:GE Healthcare Ltd. and its Affiliates | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (F 18) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coro... | |||||||||||||
Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of Flurpiridaz (F 18) Injection in patients with suspected coronary artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) NL (Ongoing) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006295-17 | Sponsor Protocol Number: MedTrace-002 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:MedTrace Pharma | |||||||||||||
Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con... | |||||||||||||
Medical condition: Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000826-22 | Sponsor Protocol Number: CBLZ945C12201 | Start Date*: 2019-09-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020352-59 | Sponsor Protocol Number: GHF112670 | Start Date*: 2010-07-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III ... | |||||||||||||
Medical condition: NYHA Class II/III congestive heart failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.